GlassScriptPhysician profile
Julije Vucemilovic
NPI 1053318329
$1,373.73
in general payments reported to CMS, 2019-2025
13 companies · $43.31 in 2025
The $43.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $435 · 2021: $478 · 2022: $110 · 2023: $182 · 2024: $124 · 2025: $43.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.84 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.65 | 2020-2022 | |
| Eisai INC. | $236.21 | 2020-2021 | |
| Lilly USA, LLC | $200.34 | 2020-2025 | Kisunla, Trulicity, Mounjaro |
| Amarin Pharma, INC. | $172.96 | 2020 | |
| Glaxosmithkline, LLC. | $144.07 | 2023 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $109.42 | 2021 | |
| Abbott Laboratories | $77.08 | 2024 | Mitraclip |
| Novo Nordisk INC | $70.65 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $29.39 | 2020 | |
| Axonics, INC. | $21.21 | 2021 | |
| Smith+Nephew, INC. | $14.24 | 2020 | |
| Amgen INC. | $13.89 | 2023 | |
| Pfizer INC. | $13.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julije Vucemilovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.